Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Implants / Devices
    • Abbotts recent deals,...

    Abbotts recent deals, medical device pipeline to fuel growth

    Written by Ruby Khatun Khatun Published On 2017-10-21T10:11:15+05:30  |  Updated On 21 Oct 2017 10:11 AM IST
    Abbotts recent deals, medical device pipeline to fuel growth

    Abbott Laboratories quarterly results beat estimates and the company raised the top end of its full-year earnings forecast range on Wednesday, as a string of recent deals and medical device approvals help spur growth in its largest unit.


    The company has acquired several rivals this year, including St. Jude Medical and Alere, to bolster its medical devices business, and favorable tax laws in India are boosting its generics business.


    The company's shares rose 2.8 percent to $56.60 to a record in morning trading.


    Strength in medical devices pulled this quarter, while recent product approvals put Abbott in a good position, Jefferies analyst Raj Denhoy told Reuters.


    Sales in the medical devices business rose 6.5 percent to $2.60 billion, accounting for more than a third of total sales.


    The generics unit, which sells drugs in emerging markets, brought in sales of $1.17 billion, up 16 percent.


    Sales in India, a key market for the company, were helped as the implementation of the new Goods and Services Tax prompted inventory restocking.


    Abbott said it now expects full-year adjusted 2017 profit from continuing operations of $2.48-$2.50 per share, compared with its previous range of $2.43-$2.53.


    Chief Financial Officer Brian Yoor said he expects the recently closed Alere deal to contribute around $475 million to reported sales this year.


    Sales in Abbott's nutrition unit, which had been under pressure due to challenges in China, rose marginally. "We've seen a stabilizing of China; it hasn't been as choppy as it was in the last 2 years," Chief Executive Miles White said.


    Abbott and other makers of infant formula have struggled to boost sales in China after the country made it mandatory last year for manufacturers to re-register baby formulas with the government.


    During the quarter, the U.S. Food and Drug Administration approved several of Abbott's devices, including the FreeStyle Libre glucose monitoring system and heart devices HeartMate 3 and Ellipse.


    "Overall, we'd expect investors to view these results positively - not just for ABT, but again for the broader med-tech group," Leerink analyst Danielle Antalffy said.


    Net sales of $6.83 billion beat the average analyst estimate of $6.72 billion, according to Thomson Reuters I/B/E/S. Excluding items, profit was 66 cents per share, beating estimates by a penny.


    (Reporting by Manas Mishra and Akankshita Mukhopadhyay in Bengaluru; Editing by Martina D'Couto and Saumyadeb Chakrabarty)

    AbbottAbbott IndiaAbbott LaboratoriesBrian YoorGoods and Services TaxgrowthIndiamedical deviceMiles WhitepipelineRaj DenhoyU.S. Food and Drug Administration
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok